# Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

> **NCT03531645** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Malignant Neoplasms of Female Genital Organs

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT03531645
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-13
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531645, "Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT03531645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*